{"nctId":"NCT01806259","briefTitle":"Ketorolac in Breast Cancer Surgery","startDateStruct":{"date":"2013-02","type":"ACTUAL"},"conditions":["Curative Breast Cancer Surgery","Inflammatory Positive/Negative Status","Pre Surgical Incision Administration"],"count":203,"armGroups":[{"label":"ketorolac 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ketorolac 30 mg IV"]},{"label":"NaCl 0.9% 3mL","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Ketorolac 30 mg IV","otherNames":["ketorolac tromethamine"]},{"name":"Placebos","otherNames":["NaCl 0.9%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nWritten informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes ratio \\>4 and/or \"triple negative\" histological status and/or Positive lymph nodes\n\nExclusion Criteria:\n\nPrevious cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) Non compliance or refusal of the protocol Positive Pregnancy test Childbearing or breastfeeding mothers Contra-indication for NSAIDs NSAIDs intake in the 5 days before randomisation NSAIDs use planned in the 30 days after randomisation Non curative surgery (T4 or M1 tumor classification )","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence-free Survival","description":"2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Survival","description":"2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":96},"commonTop":[]}}}